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Nanocarriers responding to specific stimulus have revealed high potential for achieving 
on-demand release in a spatiotemporally controlled manner and improved treatment modalities. 
Particularly, nanocarriers responding to intracellular redox-potential have represented a promising 
strategy for achieving selective intracellular delivery of therapeutic agents and avoiding detrimental 
side effects to normal tissues. Owing to the essential role of endosomal escape for disulfide-based 
nanocarriers due to the insufficient reduction potential of endocytic compartments, endowing such 
nanocarriers with an additional external stimulus to induce cytosolic translocation may provide further 
spatial and temporal manipulation at the targeted tissue region. Moreover, the precise operation at the 
site of triggering can eliminate detrimental issues rising from the off-target distribution of these drug 
delivery systems.  
Polymeric micelles incorporating therapeutic agents in their core have demonstrated 
outstanding features as nanocarriers in both preclinical and clinical studies, including their adaptable 
drug release in response to specific stimuli by directly engineering the bond between the drugs and the 
core-forming segment of the block copolymers. Our group has previously developed polymeric 
micelles exploiting disulfide bonds in their core for specifically acting under the reductive conditions 
of the cytosol, which shows 100- to 1000-fold higher glutathione (GSH) concentration than those in 
blood and extracellular milieu. As polymeric micelles enter cells via endocytosis and accumulate in 
endosomal/lysosomal compartments with insufficient redox-potential for thiol/disulfide exchange 
reaction, micelle systems sensitive to reductive cytosolic environment could be effectively combined 
with external stimuli for spatiotemporal controlling the therapy after inducing their escape from 
endosomes into the cytosol.  
Herein, I developed drug-loaded polymeric micelles designed to release their content under 
the reductive condition of the cytosol and exploit an external trigger, namely, reactive oxygen species 
induced by light-irradiated photosensitizers capable of permeabilizing endosomal membranes, so called 
photochemical internalization (PCI), for allowing these micelles to escape from endosomes into the 
cytosol and controlling their drug release in situ. In Chapter 2 of this thesis, these reduction-sensitive 
micelles were self-assembled in water after conjugating the anticancer drug camptothecin (CPT) to the 
poly(L-lysine) block of poly(ethylene glycol)-poly(L-lysine) (PEG-P(Lys)) block copolymers via a 
reduction-sensitive disulfide linker and their physicochemical properties were evaluated. The 
drug-conjugated ratio can be effectively controlled from 5 to 16% (w/w) by modulating the feeding 
amount of CPT (1, 2, and 5 eq.). According to the dynamic light scattering (DLS) and transmission 
electron microscopy (TEM) analysis, the sub-100 nm micellar size and condensed PEG shell can 
confer improved tumor accumulation through the enhanced permeability and retention (EPR) effect, 
that is, the enhanced accumulation of macromolecules in tumor tissues due to the augmented 
permeability and reduced lymphatic drainage, and prolonged retention time in bloodstream for further 
in vivo application. The drug release study of CPT/m using GSH or dithiothreitol (DTT) as the 
reducing agents showed preferential release at reductive conditions simulating the cytosol, and the 
negligible release of these micelles at extracellular conditions. As the hydrophobic drug was covalently 
conjugated with the thiolated block copolymer, the preferential intracellular release and excellent 
extracellular stability suggested the reduction-sensitive micelles could be a promising platform for the 
delivery of hydrophobic agents.  
The in vitro cell viability of various cancer cells after incubation with free CPT and CPT/m 
was studied in Chapter 3 of this thesis to determine the cytotoxic effect of these micelles. CPT/m 
showed usually 100-fold lower cytotoxicity than the free drug, indicating the safety of these micelles 
and suggesting the limited intracellular drug release without the activation. Both drugs were further 
combined with 0.1 μg/ml the clinically used photosensitizer Photofrin in Chapter 4, which was found 
to be non-cytotoxic after 10 min irradiation with white light at 1.8 J/cm2, for inducing endosomal 
escape of the micelles. While without light irradiation, free CPT plus Photofrin showed approximately 
100-fold lower 50% inhibitory concentration (IC50) than micelles alone, 10 min irradiation of CPT/m 
plus Photofrin enhanced the cytotoxicity of the micelles, showing more than 3-fold decrease in the 
IC50 compared to the non-irradiated sample. Even 0.01 μg/ml Photofrin and 10 min irradiation induced 
the enhancement of in vitro cytotoxicity of CPT/m, suggesting the capability of Photofrin for 
improving the efficacy of these reduction-sensitive micelles. This enhancement of the cytotoxicity of 
CPT/m could be attributed to the photo-induced permeabilization of endocytic membranes by the 
generated ROS species from Photofrin after light exposure, followed by the endosomal escape of 
micelles and the accelerated release of CPT.  
The capability of Photofrin to induced endosomal escape of CPT/m by PCI was evaluated in 
vitro by following the time-dependent intracellular distribution of CPT/m labeled with Alexa 555 in 
AY27 cancer cells via confocal laser scanning microscopy (CLSM). The late endosomes of AY27 cells 
were marked by using CellLight Late Endosome-GFP. These cells were incubated with Alexa 
555-labeled CPT/m and Photofrin for 24 h. At this time-point, the signal of micelles was colocalized 
with that of late endosomes. Then, the cells were irradiated with a light dose similar to that of the in 
vitro cytotoxicity experiment, that is, 1.8 J/cm2, and the escape of the micelles from the late endosomes 
was followed by assessing the CPT/m/endosomes colocalization ratio. After 2 h, the endosomal escape 
of Alexa 555-labeled CPT/m in irradiated cells was evident, whereas the cells without light irradiation 
maintained the level of colocalization of micelles with late endosomes. Thus, this PCI-mediated 
translocation of CPT/m from endosomal compartments into the reductive cytosol may result in the 
enhanced intracellular release of CPT, which could be a substantial advantage for developing safe and 
tumor-specific cytotoxic therapies. 
In Chapter 5, the in vivo performance of CPT/m and the feasibility of the therapeutic 
strategy were evaluated in detail. For effectively exploiting the selective tumor accumulation through 
EPR effect, CPT/m should stably circulate in the bloodstream for prolonged time. Therefore, in 
Chapter 5, we assessed the in vivo circulation time of CPT/m in the bloodstream by using in vivo 
confocal laser scanning microscopy, which allows real-time non-invasive and quantitative evaluation of 
in vivo dynamic processes. Thus, the fluorescence intensities of Fluorescently-labeled CPT/m in the 
blood vessels of the ear-lobe, as well as in the interstitial space, were followed for more than 15 h. 
Snap-shots at 1 min and 1, 6 and 15 h post i.v. injection of the micelles and quantification of the signal 
in the blood vessels revealed that the Fluorescently-labeled CPT/m have prolonged circulation in the 
bloodstream for more than 15 h, with a blood half-life of 12.8 h, which is probably associated with the 
surface, size and controlled release rate of the micelles. Moreover, CPT/m did not extravasate into the 
interstitial space of the ear lobe, indicating that the micelles did not dissociate into the forming block 
copolymers during blood circulation. Moreover, the blood circulation of Photofrin after i.v. injection 
was also evaluated. The half-life of Photofrin in blood was calculated to be 7.9 h. Contrary to CPT/m, 
Photofrin gradually extravasated into the interstitial space of healthy skin tissue, which is associated 
with its skin phototoxicity reported in the clinic. It is worth mentioning that, even though the PS 
molecules accumulate in healthy tissue, the strategy proposed in this study can overcome such 
drawback as the extravasation and accumulation of CTP/m in healthy tissue is minimal and the PS 
doses required for PCI are nontoxic, which may result in safe light-activated chemotherapies. 
Considering the significant role of Photofrin in PDT against bladder cancer, as well as the 
requirements for avoiding typical symptoms of PDT to healthy bladder, the in vivo antitumor effects 
resulting from the PCI-mediated activation of CPT/m were studied in Chapter 5 against a xenograft 
tumor model of AY27 rat bladder cancer. Accordingly, 24 h after i.v. administration, the amount of CPT 
delivered by CPT/m in subcutaneous AY27 xenografts was determined to be 11% of the injected dose 
per gram of tumor. The effect of Photofrin-induced PCI on the in vivo antitumor activity of CPT/m was 
then evaluated in nude mice bearing subcutaneous AY27 xenografts. Mice treated with 3 i.v. injections 
every 2nd day, i.e. on days 0, 2 and 4, of Photofrin at 2 mg/kg followed by irradiation with a light-dose 
of 10 J/cm2 (fluence rate: 100 mW/cm2) on days 1, 3 and 5 showed comparable tumor growth to mice 
receiving PBS injections, indicating that Photofrin at this dosage does not afford significant antitumor 
effect. Thus, this Photofrin dosing was used in combination with free CPT at its maximum tolerated 
dose, that is, 5 mg/kg, or CPT/m at 50 mg/kg on a CPT base, which were i.v. injected following the 
same schedule as Photofrin, for determining the enhancement of the antitumor efficacy after PCI. The 
activity of free CPT at 5 mg/kg was not affected by the induction of PCI by Photofrin, as free CPT 
enters cells by diffusion. Conversely, while CPT/m at 50 mg/kg showed moderate antitumor effect, the 
application of PCI significantly enhanced the activity of the micelles compared to PBS (P < 0.01) and 
CPT/m at 50 mg/kg groups (P < 0.05). Also, it is worth noting that, while free CPT at 5 mg/kg caused 
considerable loss of the body weight of mice (P < 0.001), and 1 out of 5 mice died at day 8 in the free 
CPT plus PCI group due to toxicity, the weight of mice treated with CPT/m at 50 mg/kg was not 
affected during the antitumor activity experiment, most likely due to the site-specific control of the 
micelles by PCI, and the controlled release of CPT from the micelles under cytosolic conditions.  
To confirm that Photofrin induced PCI of CPT/m in vivo, the intracellular distribution of 
Fluorescently-labeled CPT/m in AY27 xenografts in a living mouse was analyzed by in vivo CLSM. 
Initially, a subcutaneous AY27 tumor was surgically exposed, and the late endosomes in the cells of the 
tumor were marked by dropping 10 μl of CellLight Late Endosome-GFP on the xenograft. Twenty-four 
hours later, Photofrin at 2 mg/kg and the fluorescent micelles were i.v. injected. After 24 h, the micelles 
were visualized in the late endosomes of the cells in the tumor. In addition, Hoechst 33342 was used to 
stain the nucleus of AY27 cancer cells to distinguish the position of single cells. After irradiating with a 
light-dose of 2.0 J/cm2 (fluence rate: 100 mW/cm2), the signal from CPT/m gradually separated from 
that of late endosomes, indicating the endosomal escape of the micelles. Conversely, in a non-irradiated 
tumor, the colocalization of the micelles and late endosomes was observed throughout the experiment. 
Moreover, the colocalization ratio of micelles and late endosomes was reduced from 70% to 59% 5 h 
after irradiation. The facilitated access of CPT/m to the cytosol after PCI, observed in these intravital 
microscopies, may promote the drug release from the micelles within the tumors, improving their 
therapeutic efficiency. 
Twenty-four hour after co-injection of CPT/m and Photofrin, the tumors were irradiated at a 
light dose of 10 J/cm2 to induce the PCI effect. Then, the PCI-induced release of CPT from CPT/m 
within AY27 tumors was assessed by calculating the amount of free CPT at 0 and 24 h after irradiation 
obtained by reverse phase liquid chromatography of homogenized tumor tissues. Thus, while the 
released of CPT from the micelles within tumors without irradiation was less than 4%, the drug release 
was more than 70% 24 h after irradiation. This increment of CPT release was further demonstrated by 
studying the fluorescence of CPT in tumor sections by using CLSM. Accordingly, after PCI, the 
fluorescence signal from CPT in tumor tissues augmented due to the release and dequenching of the 
CPT molecules that were loaded in the core of CPT/m, whereas in non-irradiated tumor tissues CPT 
molecules remained quenched in the core of micelles. These results support the enhancement of the in 
vivo antitumor activity of CPT/m after the application of PCI, and denote the ability of 
reduction-sensitive drug-loaded polymeric micelles for developing safe and site-specific 
chemotherapies activated by PCI. Moreover, other external stimuli capable of permeabilizing 
endosomal membranes could be potentially combined with polymeric micelles releasing their payloads 
in response to cytosolic signals for designing highly selective antitumor treatments. 
In this study, we designed and developed reduction-sensitive polymeric micelles for 
selectively release of CPT under cytosolic conditions, and demonstrated their practicality as safe 
nanocarriers for effective light-activated chemotherapy in combination with Photofrin. To our 
knowledge, this is the first study demonstrating in real-time the controlled operation of nanocarriers 
from endosomal compartments after application of light in vivo, which not only allowed us to confirm 
the design of our strategy by direct visualization of the process, but could also serve for expanding the 
insights of the intracellular processes for other nanocarriers and therapeutics after the application of 
triggers permeabilizing endosomal membranes in situ. The specific features of these micelles can be 
remotely controlled after promoting their escape from endosomal compartments in cells within tumors 
by PCI, to exert strong inhibition of the tumor growth without toxicity. This first demonstration of 
PCI-induced endosomal escape indicated the capability of spatiotemporal control of the cytosolic 
activation of reduction-sensitive micelles for developing safe and effective therapies, and suggested the 
potential of modulating biological events within diseased tissues by using exogenous triggers for 
amplifying the activity nanocarriers. Moreover, since a broad variety of therapeutic agents can be 
incorporated inside polymeric micelles through disulfide coupling, the design of reduction-sensitive 
polymeric micelles can be readily tailored to fulfill the therapeutic requirements and facilitate the 
development of PCI-activated therapies with clinical potential. 
 
